Free GO PUBLIC Checklist — Evaluate your SPAC readiness

Patrick A. Sturgeon

Patrick A. Sturgeon Profile Photo

Investment Banker

Patrick Sturgeon is a Managing Partner at Brookline Capital Markets, where he leads capitalformation, capital deployment, and strategic transactions across public and private markets. With experience spanning investment banking, SPAC sponsorship and CFO leadership, and venture capital, over the last decade he has raised in excess of $3 billion, executed over $2.5 billion in M&A, and completed more than 50 transactions, including 32 IPOs.

He operates at the intersection of capital markets and high-growth sectors, working with founders, executives, and institutional investors on capital deployment, transaction
execution, and strategic growth initiatives across global markets.

Mr. Sturgeon has served as Chief Financial OMicer of three SPACs, each successfully completing acquisitions and transitioning to the public markets, including Humacyte
(NASDAQ: HUMA), Apexigen (NASDAQ: APGN), and Carmell Therapeutics, now Longevity Health Holdings (NASDAQ: XAGE), where he currently serves as Vice Chairman and
remains actively involved in governance and strategic oversight.

As a Founding Partner of Covenant Venture Capital, he has led the deployment of approximately $100 million in direct investments across high-growth sectors including
artificial intelligence, defense technology, and data analytics. Covenant’s investments include companies such as Anduril, Anthropic, Dataminr, KrateoSky, OpenAI, Palantir,
Saronic and SpaceX. He also led the firm’s designation as a Qualified Venture Fund with the New Jersey Economic Development Authority (NJEDA), enabling access to state matched capital.

In addition to his investing and transaction work, Mr. Sturgeon serves on the Advisory Board of ZeroToOne.AI, a technology platform focused on enterprise applications of artificial intelligence, and is a frequent speaker on equity capital markets, transaction execution, and emerging growth sectors.

Earlier in his career, Mr. Sturgeon was a Managing Director at Axiom Capital Management and a Vice President at Freeman & Co., where he advised financial services companies on
M&A and strategic transactions.

Mr. Sturgeon holds an MBA from the NYU Stern School of Business and a BS in Economics from the University of Massachusetts at Amherst.

What Makes a Good SPAC Target (and What Disqualifies One)
June 30, 2026

What Makes a Good SPAC Target (and What Disqualifies One)

What actually disqualifies a private company from a SPAC deal? Patrick Sturgeon says the answer is often the same thing that would sink a traditional IPO — size. A single-asset biotech at Phase 1B with a sub-$100M valuation "just should not be a public company," and the exchanges are taking a harder look at microcaps trying to list. In this episode, Chaz Churchwell sits down with Dimitre Genov, Managing Director, and Patrick Sturgeon, Managing Partner at Brookline Capital Markets, for a practiti...